Yoshikawa Kiyotsugu, Hagimoto Hiroki, Nakamura Eijiro
Laboratory of Pharmacotherapy, Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts.
Department of Urology, National Cancer Center Hospital.
Nihon Yakurigaku Zasshi. 2024;159(3):160-164. doi: 10.1254/fpj.23090.
The 2019 Nobel Prize in Physiology or Medicine was awarded to Dr. William G. Kaelin Jr, Dr. Peter J. Ratcliffe, and Dr. Gregg L. Semenza for their elucidation of new physiological mechanisms "How cells sense and adapt to oxygen availability". Moreover, two different drugs, HIF-PH inhibitors and HIF-2 inhibitors were also developed based on the discovery. Interestingly, those three doctors have different backgrounds as a medical oncologist, a nephrologist, and a pediatrician, respectively. They have started the research based on their own unique perspectives and eventually merged as "the elucidation of the response mechanism of living organisms to hypoxic environments". In this review, we will explain how the translational research that has begun to solve unmet clinical needs successfully contributed to the development of innovative therapeutic drugs.
2019年诺贝尔生理学或医学奖授予威廉·G·凯林博士、彼得·J·拉特克利夫博士和格雷格·L·塞门扎博士,以表彰他们对“细胞如何感知和适应氧气供应”这一新生理机制的阐释。此外,基于这一发现还开发了两种不同的药物,即低氧诱导因子脯氨酰羟化酶(HIF-PH)抑制剂和HIF-2抑制剂。有趣的是,这三位医生背景各异,分别是医学肿瘤学家、肾病学家和儿科医生。他们从各自独特的视角出发开展研究,最终汇聚成“对生物体低氧环境反应机制的阐释”。在本综述中,我们将解释已开始解决未满足临床需求的转化研究如何成功推动了创新治疗药物的研发。